The Remaining Smallpox Virus Stocks Are Too Valuable To Be Destroyed

Smallpox, or variola, virus has killed more human beings than any other infectious agent. Fortunately, smallpox virus has only one host-humans -- which made it possible to eradicate it. In 1967, the World Health Organization (WHO) initiated a brilliant campaign that, within 10 years, eradicated smallpox virus from human populations, the last case occurring in Somalia in 1977. Illustration: John Overmeyer Soon after, the question arose as to what to do with the smallpox isolates stored in lab

Written byWolfgang Joklik
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Smallpox, or variola, virus has killed more human beings than any other infectious agent. Fortunately, smallpox virus has only one host-humans -- which made it possible to eradicate it. In 1967, the World Health Organization (WHO) initiated a brilliant campaign that, within 10 years, eradicated smallpox virus from human populations, the last case occurring in Somalia in 1977.

Illustration: John Overmeyer Soon after, the question arose as to what to do with the smallpox isolates stored in laboratories throughout the world. In 1981, WHO recommended that all isolates be destroyed, with the exception of stocks held at the Centers for Disease Control in Atlanta and at the Institute for Viral Preparations in Moscow. WHO also recommended that the genomes of several smallpox virus isolates be cloned into plasmids and sequenced. With that achieved, some scientists and government officials claimed that the smallpox virus stocks in Atlanta and Moscow are superfluous, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies